intraoperative cisplatin system (PRV211) / Privo Tech - LARVOL DELTA

Safety and Efficacy Study of PRV111 and PRV211 in Subjects With Oral Squamous Cell Carcinoma (clinicaltrials.gov) - P2/3 | N=40 | Recruiting | Sponsor: Privo Technologies | Trial completion date: Oct 2026 ➔ May 2027 | Trial primary completion date: Aug 2025 ➔ Oct 2026

Trial completion date • Trial primary completion date • Oncology • Oral Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Privo Technologies Expands CLN-004 Clinical Trial Across Leading U.S. Cancer Centers (PRNewswire) - "Privo Technologies...is thrilled to announce the activation of multiple premier clinical sites across the United States for its ongoing CLN-004 trial. This Phase 2/3, open-label, two-arm study is evaluating the safety and efficacy of two of Privo's lead assets-PRV111 and PRV211-in patients with head and neck squamous cell carcinoma (HNSCC)....Additional leading cancer centers are in the process of being activated and will be announced in the coming weeks."

Trial status • Squamous Cell Carcinoma of Head and Neck

Safety and Efficacy Study of PRV111 and PRV211 in Subjects with Oral Squamous Cell Carcinoma (clinicaltrials.gov) - P2/3 | N=40 | Recruiting | Sponsor: Privo Technologies | Phase classification: P1/2 ➔ P2/3

Phase classification • Surgery • Oncology • Oral Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Safety and Efficacy Study of PRV111 and PRV211 in Subjects with Oral Squamous Cell Carcinoma (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: Privo Technologies | Trial primary completion date: Jan 2025 ➔ Aug 2025

Surgery • Trial primary completion date • Oncology • Oral Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Safety and Efficacy Study of PRV211 in Subjects With Oral Squamous Cell Carcinoma (clinicaltrials.gov) - P1/2 | N=40 | Recruiting | Sponsor: Privo Technologies | Not yet recruiting ➔ Recruiting

Enrollment open • Surgery • Oncology • Oral Cancer • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Safety and Efficacy Study of PRV211 in Subjects With Oral Squamous Cell Carcinoma (clinicaltrials.gov) - P1/2 | N=40 | Not yet recruiting | Sponsor: Privo Technologies

New P1/2 trial • Surgery • Oncology • Oral Cancer • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck